Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats migraine. Sold as Emgality. Every FDA application for this active ingredient.
As of Nov 22, 2026, FDA lists 1 application for Galcanezumab-gnlm (sold as Emgality), first approved Sep 27, 2018, with 1 new use approved and 0 published complete response letters.
Each condition ChEMBL records for this drug, with the furthest stage reached and the trials it cites; approved means approved for that use somewhere, not necessarily in the US
Cases reported to FDA naming this drug as the primary suspect, 2025 Q4 to 2026 Q3, from FDA's quarterly files. A report does not show the drug caused the event.
Injection site pain (1,094), Incorrect dose administered (426), Incorrect dose administered by device (316), Migraine (288), Injection site haemorrhage (233), Drug dose omission by device (233), Headache (209), Drug ineffective (81), Injection site bruising (72), Off label use (69)
Approvals in the EU (EMA)
First approved in the EU 2 months after the US. Centrally authorised medicines, matched by ingredient; see all EU approvals
First approved in Japan 28 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Emgality, new ingredientDrugs with a new active ingredient indicated for the prevention of migraine attacks. · Eli Lilly Japan K.K. · Jan 22, 2021 · Review report
Approvals in Canada (Health Canada)
First approved in Canada 10 months after the US. New drug submissions since 1994, matched by ingredient; see all Canadian approvals
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered.Drugs@FDA